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Abstract
Background: The World Health Organization recommends universal and quality-controlled screening of blood
donations for the major transfusion-transmissible infections (TTIs): human immunodeficiency virus (HIV), hepatitis B
virus (HBV), hepatitis C virus (HCV) and syphilis. The study objectives were to determine the seroprevalence of
these TTIs among blood donors at the Provincial Hospital of Tete, Mozambique, and to assess the local pre-
donation screening performance.
Methods: All consenting voluntary and replacement candidate blood donors were consecutively included from
February to May 2009. Sera of all candidates, independent of deferral by questionnaire, were submitted to
screening with quality-assured rapid or simple assays for HIV, HBV surface antigen (HBsAg), HCV and syphilis. Assays
locally used by the blood bank for HBV and syphilis screening were run in parallel to quality-assured external
assays supplied during the study, and all discordant samples were submitted to confirmation testing in reference
laboratories in Mozambique and Belgium.
Results: Of 750 consenting candidates (50.5% of voluntary donors), 71 (9.5%) were deferred by the questionnaire,
including 38 specifically because of risk behavior for TTI. Of the 679 non-deferred candidates, 127 (18.7%) had
serological confirmation of at least one TTI, with a lower prevalence in voluntary than in replacement donors
(15.2% versus 22.4%, p = 0.016). Seroprevalence of HIV, HBsAg and syphilis infections was 8.5%, 10.6 % and 1.2%.
No confirmed HCV infection was found. Seroprevalence of TTIs was similar in the 38 candidates deferred for TTI risk
as in the non-deferred group, except for HBsAg (26.3 % versus 10.6 %; p = 0.005). The local assays used for HBV
and syphilis had sensitivities of 98.4% and 100% and specificities of 80.4% and 98.8% respectively. This resulted in
the rejection of 110 of the 679 blood donations (16.2%) because of false positive results.
Conclusions: The seroprevalence of TTIs after questionnaire screening is high in Tete, Mozambique, but HCV
infection does not appear as a major issue. The questionnaire did not exclude effectively HIV-infected donor
candidates, while the locally used assays led to unnecessary rejection of many safe donations. A contextualized
questionnaire and consistent use of quality-assured assays would considerably improve the current screening
procedure for blood donation.
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Every year more than 90 million units of blood are col-
lected worldwide [1]. Each transfusion carries a risk of
transmitting blood-borne pathogens, including mainly
human immunodeficiency virus (HIV), hepatitis B virus
(HBV), hepatitis C virus (HCV) and syphilis. To improve
blood transfusion safety, the World Health Organization
(WHO) recommends an integrated strategy including
establishment of well-organized blood transfusion ser-
vices, prioritization of blood donation from voluntary
non-remunerated donors, screening of donated blood
f o ra tl e a s tt h ef o u rm a j o rt r ansfusion-transmissible
infections (TTI) with quality-assured assays, rational use
of blood and implementation of effective quality control
systems [2]. Selection of blood donors with low TTI risk
followed by effective laboratory screening is the critical
part of the process, since it has reduced the risk of
transmission to very low levels in the past 20 years [3,4].
Nevertheless, particularly in low-resource countries, a
significant proportion of donated blood remains unsafe
as it is either not screened for all major TTIs or not in
a quality-controlled manner [1,5].
Africa faces the highest transfusion needs in the
w o r l d ,b u ta l s ot h eh i g h e s tp revalence of blood-borne
pathogens and the weakest transfusion programs [6].
Most blood banks in Africa are small, hospital-based
and relying on an important proportion of replacement
donors, in contrast with western transfusion units orga-
nized with large pools of voluntary donors [7]. In addi-
tion, recommended reference screening tests like
enzyme immunoassays (EIA) or nucleic acid testing
(NAT) are technically, logistically and financially still far
beyond reach of many resource-constrained blood banks
[8]. In such settings with limited capacity and low
throughput, WHO accepts the use of rapid and simple
serological assays for TTI screening, provided that they
are quality-assured, locally validated and quality-con-
trolled. Rapid test-based screening protocols tend to be
used increasingly in African blood banks [9]. It seems
indeed effective at least for HIV and HCV screening
[10], although safety of such a strategy has been recently
challenged in an international quality control survey
[11]. For some experts, rapid testing has also the advan-
tage of immediate counseling of infected candidates and
referral to appropriate care, although this is not the pri-
mary objective of transfusion medicine [12].
In the province of Tete (3 million inhabitants), central
region of Mozambique, prevalence of HIV and syphilis
infections among pregnant women was about 13% and
7% respectively in the national sentinel surveillance
round of 2007 [13]. Provincial prevalence of HBV and
HCV infections was not known. In the reference provin-
cial hospital of Tete (PHT), more than 2,500 blood
transfusions were administered every year; about half of
them were obtained from voluntary donors. Candidate
blood donors underwent a first screening by the
national questionnaire, and non-deferred candidates
were then routinely screened for HIV, HBV and syphilis
by means of rapid or simple assays. HIV testing was
performed with internationally quality-assured assays
(see definition under Methods), while HBV and syphilis
infections were usually screened by a variety of brands,
depending on “ad-hoc” supply of the Ministry of Health
(MoH), and not always complying with international
quality criteria. There was no screening for HCV at the
time this study was conducted (2009).
The main objectives of this study were to determine
the seroprevalence of HIV, HBV, HCV and syphilis
infections in blood donors of the provincial hospital of
Tete and to assess the screening performances of the
national questionnaire and of the rapid assays used
locally for HBV and syphilis detection.
Methods
Study design and population
A cross-sectional study was set up in the blood bank of
the provincial hospital of Tete from February till May
2009. The study was executed by the regular blood bank
staff, which got an additional training prior to the start
of the study and respected the national blood transfu-
sion guidelines. All consecutive candidate blood donors,
either voluntary or replacement, were invited to partici-
pate and after signing the informed consent, enrolled.
The study complied with the STROBE recommenda-
tions for reporting on cross-sectional diagnostic studies
and with the STARD guidelines for comparisons
between diagnostic tests [14,15].
Questionnaire and blood sampling
All consenting candidate donors underwent first the
national selection questionnaire (Table 1). In accordance
with Mozambican guidelines, candidate donors were
deferred when they answered “yes” to at least one ques-
tion (except for the question number 7, formulated nega-
tively, for which a “no” answer caused deferral). A donor
was deferred definitively when he was older than 65 years
of age (question 1), had a chronic disease (question 2) or
was at risk of having a sexual transmitted infection (STI)
(questions 3 to 6). He was deferred temporarily when not
being knowledgeable about HIV transmission modes
(question 7) or having been refused for donation in the
past (question 8). Other reasons for temporary exclusion
were the presence of a pathologic condition at the
moment of donation (question 9-18), the presence of
another condition not compatible with donation (ques-
tion 19-22: pregnancy, menstruation, medication, recent
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laboratory contra-indication (items 23-28). Filling accu-
rately this questionnaire requires at least 30 minutes,
including the translation from Portuguese to the local
language.
Whole blood of candidates not deferred by question-
n a i r ew a sc o l l e c t e da n ds e r u m( b l o o ds a m p l eo f1 0m l
in a dry tube) was tested for HIV, HBV, syphilis and
HCV (see below). After testing, all serum samples were
stored at -20°C in Tete until shipment for external qual-
ity control at the “Instituto Nacional da Saude” (INS) in
Maputo, Mozambique and the Institute of Tropical
Medicine (ITM) in Antwerp, Belgium.
To assess the selective performance of the national
selection questionnaire, whole blood of deferred candi-
dates was also collected after informed consent and
tested in the same way as for non-deferred donors.
Rapid test screening and confirmatory procedures
For this study, and by analogy to the quality assurance
process for drugs [16], we considered as “quality-
assured” diagnostic tests which have been validated by
the WHO (and included in the WHO bulk procurement
list) or by a stringent regulatory authority, or which
have received the WHO prequalification attestation.
HIV testing
Presence of HIV-1 and HIV-2 antibodies was screened
with the quality-assured rapid test Determine HIV-1/2
(Abbott Laboratories, Illinois, USA), which has a reported
sensitivity of 100% and specificity of 99.4% [17]. For study
purposes and in accordance with national algorithms for
diagnostic HIV testing, blood found positive was there-
after tested for confirmation with another quality-assured
rapid test Uni-Gold HIV-1/2 (Trinity Biotech, Dublin,
Ireland) which is 100% sensitive and specific on whole
Table 1 Mozambican screening questionnaire for blood donation and main reasons for deferral in this study (n = 71)
Questionnaire Number of persons excluded per
question (n = 71)
Questions for definitive exclusion
01 Do you have more than 65 years of age? 0 (-)
02 Do you have a disease without cure (chronic)? 2 (2.6%)
03 Were you once suspected of being infected with HIV? 1 (1.3%)
04 Did you have once hepatitis/jaundice? 4 (5.1%)
05 Did you already have once a venereal disease? 22 (28.2%)
06 Do you belong to a risk group for HIV infection (injection of drugs, sexual contacts without condom,
traditional vaccines with blades used for different persons, several blood transfusions)?
6 (8.5%)
Questions for temporary exclusion
07 A person with HIV can not donate blood? 4 (5.1%)
08 Were you refused before to donate blood? 1 (1.4%)
09 Do you suffer from diseases of the cardiovascular system (e. g pericardial pain)? 2 (2.6%)
10 Do you suffer from diseases of the respiratory system (e.g., asthma)? 6 (8.5%)
11 Do you suffer from diseases of the gastrointestinal system (e.g.; peptic ulcer) 1 (1.4%)
12 Do you suffer from diseases of the central nervous system (e.g. epilepsy)? 1 (1.4%)
13 Do you suffer from diseases of the muscular/skeletal system? 0 (-)
14 Do you suffer from diseases of the genital/urinary system? 0 (-)
15 Do you suffer from diseases of the endocrine system? (e.g. diabetes). 0 (-)
16 Do you suffer from diseases of the immune system? (e.g. allergy) 1 (1.4%)
17 Do you have a blood disease? (e.g. hemophilia)? 0 (-)
18 Do you have a fever? 3 (5.1%)
19 Are you pregnant /menstruating? (women) 2 (2.6%)
20 Are you taking any medication? 0 (2.6%)
21 Were you vaccinated in the last 4 weeks? 1 (1.4%)
22 Were you operated in the last 6 months? 0 (-)
Physical examination
23 Control if donor has infectious diseases 0 (-)
24 Do you have a blood pressure higher than 160/110 mmHg or lower than 120/80 mmHg? 1 (1.4%)
25 Do you have a pulse higher than 120 beats per minute (bpm) or lower than 70 bpm? 0 (-)
26 Do you have a weight below 50 kg? 5 (6.4%)
27 Do you have a hemoglobin level below 12.5 g/dl? 3 (3.8%)
28 Others 5 (7.0%)
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ment 2010 list for HIV test kits. Reported HIV seropreva-
lence corresponds to the proportion of cases tested
positive with both tests [18].
HBV testing
Hepatitis B surface antigen (HBsAg) testing was per-
formed with the rapid test Healthease HBsAg (Neome-
dic Ltd., Sea Cow Lake, South Africa) supplied by the
MoH and in use in the blood bank. However, since this
test lacked independent quality assurance data, another
rapid test, Determine HBsAg (Abbott Laboratories, Illi-
nois, USA), from the WHO bulk procurement 2010 list,
was supplied by ITM and run in parallel during the
study (reported sensitivity: 100%; specificity: 99.4% [19]).
In case of discordant results, both tests were repeated to
exclude manipulation errors. All sera with persisting dis-
cordance were sent to the INS in Maputo and analyzed
by the EIA Murex HBsAg Version 3.0 (Abbott Diagnos-
tics Division, Murex Biotech Limited, Dartford, UK; sen-
sitivity: 99.7% and specificity: 99.5%). Reported HBsAg
seroprevalence corresponds to the result obtained with
the rapid test Determine HBsAg rapid test corrected by
EIA (this procedure being further considered as our
reference diagnostic method). Sensitivity and specificity
of the rapid test locally used (Healthease HBsAg) were
calculated with standard formulas against this reference
method.
Syphilis testing
For the same reason as for HBV, syphilis was screened
with 2 rapid plasma reagin (RPR) card tests in parallel:
one used routinely in the blood bank, the RPR test Ara-
Gen (AraGen Biotech, Amman, Jordan), and the quality-
assured RPR test BD Macro-Vue RPR (Becton, Dickin-
son and Company, Maryland, USA) supplied by the
ITM for this study. In case of discordant results, both
t e s t sw e r er e p e a t e d .A n yp o s i t i v eR P Rt e s tw a ss u b -
mitted in the Tete blood bank to confirmation with the
quality-assured Treponema pallidum particle agglutina-
tion (TP°PA) test: SERODIA
®- TP°PA (Fujirebio, Tokyo,
Japan). Reported syphilis seroprevalence corresponds to
the proportion of cases positive with the RPR test BD
Macro-Vue RPR further confirmed with SERODIA
®-T P
°PA (considered as our reference diagnostic method).
Sensitivity and specificity of the rapid test locally used
(Aragen) were calculated with standard formulas against
this reference method.
HCV testing
HCV testing, not performed routinely in the provincial
hospital, was added to the pre-donation serological
screening during the study period. HCV antibodies were
detected trough the quality-assured rapid test, SD BIO-
LINE HCV (Standard Diagnostics, Kyonggi-do, Korea).
Reactive samples were re-analyzed at the INS with the
EIA Murex anti-HCV version 4.0 (Abbott Diagnostics
Division, Murex Biotech Limited, Kyalami, Republic of
South Africa) as well as with the Line ImmunoAssay
(LIA) confirmatory test INNO-LIA HCV (Innogenetics,
Ghent, Belgium). Molecular confirmation and genotyp-
ing was planned in ITM for samples found positive with
LIA. Reported HCV seroprevalence corresponds to the
proportion of cases confirmed positive with LIA.
Management of blood donations and candidate donors
Blood reactive to any of the locally used or ITM-sup-
plied screening tests was discarded. All donors found
positive with any screening test were offered specific
counseling about the need for further confirmatory
workup and were informed when the confirmatory
results were available (immediately for syphilis, several
months later for HBV and HCV infections after workup
in Maputo and Antwerp). Individuals with confirmed
serological diagnosis of TTI were evaluated and mana-
ged according the current standard of care in Mozambi-
que. Donors found with positive Determine HIV-1/2 but
negative Uni-Gold HIV-1/2 (discordant results) were
immediately re-tested and in case of persistent discor-
dance were referred to the HIV counseling program
where both tests were repeated within one month
according to the national algorithm. Donors with con-
firmed HIV infection were immediately referred to the
HIV care and treatment program.
Quality control of the laboratory results
Internal quality controls were performed weekly. External
quality control took place in the INS, where all sera with
discordant rapid test results for HBsAg were analyzed with
EIA (as already mentioned). The INS retested also 10% of
the samples for which both HBsAg rapid tests had given
concordant results. All samples reactive to HCV rapid test-
ing as well as 10% of the non-reactive samples were re-
checked at the INS. External quality control of screening
and confirmatory results was also performed for all four
pathogens under investigation at the ITM in Belgium.
Sample size and statistical analysis
Since the HCV seroprevalence had never been investi-
gated in Tete and was estimated to be rather low (about
2% according to the few available regional data [20,21]),
the sample size calculation targeted specifically this con-
dition. We calculated that 750 participants had to be
included to obtain with a confidence interval (CI) of
95% a level of accuracy of +/- 1% around the expected
HCV prevalence of 2%.
Measures of prevalence were expressed in percentages
and reported with 95% confidence intervals. Compari-
sons between subgroups were done using the Pearson
Chi-Square test. All tests were 2-tailed and P < 0.05
indicated statistical significance.
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All participants were explained the purpose of the
study and signed an informed consent. The study fol-
lowed the national blood donation procedures except
that three additional quality-assured rapid tests and
three confirmatory tests were performed on collected
blood. There was no additional risk for the blood
donors. Participants were offered information on the
confirmatory procedures and referred to standard care
in case infection was confirmed. In Belgium, the study
was approved by the Institutional Review Board of the
ITM and by the Ethical Review Committee of Antwerp
University. In Mozambique approval was given by the
National Bioethical Committee and the Ministry of
Health.
Results
Seroprevalence of transfusion-transmissible infections
Of 758 candidate donors, 750 consented to participate
in the study (88.9% males, mean age 27 ± 9 years),
including 379 (50.5%) voluntary donors. Seventy-one
(9.5%) candidates were deferred by means of the screen-
ing questionnaire. The rate of rejection was similar
among voluntary (31/379; 8.2%) and replacement donors
(40/371; 10.8%).
The demographic data and laboratory results of the
679 non-deferred candidates are detailed per type of
donors in Table 2. At least one transfusion-transmitted
infection was serologically confirmed in 127 (18.7%) of
them. Prevalence of at least one TTI was significantly
lower in voluntary than in replacement donors (15.2%
versus 22.4%; p = 0.016). Seroprevalence of HIV, HBV,
HCV and syphilis infection was 8.5% (95% CI: 6.6-
10.9%), 10.6% (95% CI: 8.4-13.2%), 0.0% and 1.2% (95%
CI 0.5-2.3%) respectively (Table 2). There were eight
donors found with HIV-HBV co-infection and two co-
infected with HIV and syphilis. Prevalence of each infec-
tion was lower in voluntary than in replacement donors,
but the differences were not statistically significant
(Table 2).
For HCV infection, six samples (1.03%) were reactive
to the HCV rapid test in Tete, but none of them was
found positive with the EIA testing or with the confir-
mation LIA testing performed in Maputo (4 negative
and 2 intermediate results). Therefore, no sample had to
be submitted to molecular confirmation in Antwerp. Of
note, during the quality control of the negative HCV
rapid test results, 5 samples (on 69 tested) were reactive
to EIA, but none of them was thereafter confirmed by
LIA.
Quality control with screening and confirmatory tests
in Maputo and in Antwerp did not show any discordant
result with those obtained in Tete, except for HbsAg
results (see below).
Performance of screening questionnaire
The main reasons for deferral of the 71 candidate donors
a r es h o w ni nT a b l e1 .T h i r t y-eight candidate donors
(54%) were excluded because of STI antecedents
(answered “yes” to question 5; n = 22) or presumed risk
for STI (answered “yes” t oq u e s t i o n s3 ,4 ,6o r8 ,o r
answered “no” to question 7; n = 16). Four candidates
were excluded because of a history of jaundice (question
4), with 3 of them actually found positive for HBsAg.
Candidates deferred because of STI risk were more often
older than 25 years (25/38, 65.8% versus 331/679, 48.7%;
P = 0.04).
When comparing the seroprevalence of TTIs between
donors deferred because of sexual risk behavior (n = 38)
and non-deferred donors (n = 679), no difference could be
found, except for HBsAg positivity, more frequently
observed in the former group (26.3% vs. 10.6%, p = 0.003).
Comparisons between screening tests for HBsAg and
syphilis
A large discordance was observed between the results of
the two rapid tests for HBsAg screening: 122 samples
non-reactive to the Determine HBsAg rapid test reacted
to the Healthease HBsAg rapid test. Three of them were
found positive with the EIA performed in Maputo, and
all three samples were in fact reactive to the Determine
HBsAg rapid test when it was re-performed in Maputo
(same lot number as in Tete), suggesting that perform-
ing or reporting errors had occurred in Tete. All 119
other samples reactive to Healthease HBsAg (but not
reactive to Determine HBsAg) were negative when
tested with EIA in Maputo (Table 3). On the other
hand, one sample reactive to the Determine HBsAg
rapid test but not reactive to the Healthease HBsAg rapid
test was finally confirmed as a true positive by EIA.
Therefore, when using the results of the Determine
HBsAg rapid test corrected by EIA as reference (Table 3),
we found that the sensitivity of the Healthease HBsAg
rapid test was 98.6% (95%CI: 92.8-99.8%) and the specifi-
city 80.4% (95%CI: 79.7-80.5%).
For syphilis, there were less discordant results: four
samples reactive to the AraGen RPR test did not react to
the BD Macro-Vue RPR test. None of them was con-
firmed by SERODIA-TP°PA (Table 4). No sample nega-
tive with Aragen RPR tested positive with BD Macro-Vue
RPR. Of the 12 samples reactive to the BD Macro-vue
RPR, 8 were confirmed by SERODIA-TP°PA. When com-
pared to the reference method, the AraGen RPR test had
a sensitivity of 100% and a specificity of 98.8% (95% CI:
98.0-99.6)
Finally, 253 of the 679 (37.3%) donor candidates not
initially deferred were excluded from donation because
their blood was reactive to at least one screening test.
However, 110 (16.2%) had been in fact needlessly
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of non-quality-assured screening tests in the blood bank.
Discussion
In this study, we found a high prevalence of transfusion-
transmissible infections in blood donor candidates of
the provincial hospital of Tete, Mozambique, and in par-
ticular in replacement donors. Seroprevalence of HIV,
HBsAg, and syphilis was 8.5%, 10.6 %, and 1.2% respec-
tively, and no donor was found with confirmed HCV
infection. We observed also that the questionnaire had a
selective value for candidate donors with HBV infection,
but did not discriminate those infected with HIV or
syphilis. Finally, the rapid test for HBV screening used
by the national program had an unacceptably low speci-
ficity, resulting in a high proportion of donations need-
lessly rejected.
Several limitations are to be mentioned. The study
was conducted according to the routine practice of the
blood bank, with no additional staff or equipment. Full
time supervision (24 hours a day, 7 days a week) by the
main investigator was not possible, and errors in per-
forming or reporting may have occurred. Also, rapid
tests were compared in parallel and in a non-blinded
way, with some risk of “cross-influence” on the results.
As mentioned, sophisticated testing could only be per-
formed in Maputo, representing considerable logistical
efforts. For this reason, reference testing was not per-
formed on the whole sample set but purposely restricted
to the samples with discordant results in Tete, to all
s a m p l e sr e a c t i v et oH C Vr a p i dt e s ta n dt ot h es u b s e to f
positive and negative samples sent for quality control.
Some erroneous results of rapid testing might therefore
Table 2 Frequency of positive serological tests for, and confirmation of, HIV, HBsAg, HCV and syphilis infections in
non-deferred (voluntary and replacement) blood donor candidates at the provincial hospital of Tete, Mozambique
Total donors
(n = 679)
Voluntary
donors
(n = 348)
Replacement
donors
(n = 331)
P
Demographic data
Male 609 (89.7%) 310 (89.1%) 299 (90.3%) 0.59
Age 25-65 years 331 (48.7%) 124 (35.6%) 207 (62.5%) < 0.001
HIV testing
Positive Determine HIV-1/2 rapid test 73 (10.8%) 31(8.9%) 42 (12.7%) 0.14
Positive Determine HIV-1/2 and Uni-Gold HIV-1/2 rapid tests 58 (8.5%) 24 (6.9%) 34 (10.3%) 0.12
HBV testing (HBsAg)
Positive Determine HBsAg rapid test 69 (10.2%) 30 (8.6%) 39 (11.8%) 0.2
Positive Healthease HBsAg rapid test 190 (28.0%) 97 (27.9%) 93 (28.1%) 1.0
Positive Determine HBsAg rapid test corrected by Murex HBsAg EIA (INS) 72 (10.6%) 30 (8.6%) 42 (12.7%) 0.13
HCV testing
Positive SD Bioline HCV rapid test 6 (0.9%) 4 (1.1%) 2 (0.6%) 0.69
Positive SD Bioline HCV rapid test confirmed by INNO-LIA (INS) 0 0 0 -
Syphilis testing
Positive BD Macro-Vue RPR card test 12 (1.8%) 4 (1.1%) 8 (2.4%) 0.25
Positive AraGen RPR card test 16 (2.4%) 5 (1.4%) 11 (3.3 %) 0.13
Positive BD Macro-Vue RPR card tests confirmed by SERODIA TP°PA 8 (1.2%) 2 (0.6 %) 6 (1.8%) 0.17
At least one confirmed transfusion-transmissible infection 127 (18.7%) 54 (15.2%) 74 (22.4%) 0.016
Note: EIA denotes Enzyme ImmunoAssay; LIA Line ImmunoAssay; INS “Instituto Nacional da Saúde” (Maputo); RPR: rapid plasma reagin; TP°PA Treponema
pallidum particle agglutination.
Table 3 Comparison of Healthease HBsAg rapid test
results with reference testing (Determine HBsAg rapid
test corrected by Murex HBsAg)
Test results Reference testing:
Determine HBsAg corrected
by Murex HBsAg
Total
Positive Negative
Healthease HBsAg positive (n) 71 119 190
Healthease HBsAg negative (n) 1 488 489
Total 72 607 679
Table 4 Comparison of AraGen RPR card test with
reference testing (BD Macro-Vue RPR card test corrected
by SERODIA
®-TP°PA)
Test results Reference testing:
BD Macro-Vue RPR corrected by
SERODIA
®-TP°PA
Total
Positive Negative
RPR AraGen positive (n) 8 8 16
RPR AraGen negative (n) 0 663 663
Total 8 671 679
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of the quality control suggest that our findings were
robust. Finally, the adequacy of clinical indication for
transfusion has not been investigated here; also the
study was not designed to assess accurately the further
uptake of candidate donors diagnosed with any TTI
within clinical care programs.
L i t t l ei sk n o w no nt h es e r o p r e v a l e n c eo ft r a n s f u s i o n -
transmissible infections among blood donors in Mozambi-
que. In one such study conducted in Maputo in 2004, the
HIV prevalence was higher (13.8%) [20] than here, reflect-
ing probably the regional differences in “background” HIV
endemicity in Mozambique. In fact, our findings are in
line with those of the most recent population survey in the
province of Tete (7.0% in adults in 2009) [22]. Regarding
the prevalence of HBsAg carriage in our study population,
it was similar to that observed in blood donors in Maputo
(9.3%) [20] and in neighboring Malawi (8.1%) [23]. For
syphilis, little is known among Mozambican blood donors.
T h ep r e v a l e n c ew eo b s e r v e di sm u c hl o w e rt h a nt h a t
obtained during the last sentinel surveillance round of
2007 among pregnant women in Tete [13], but this may
be partly explained by the differences in diagnostic design:
RPR testing is indeed less specific in pregnant women
[24], and no confirmation test was used. Finally, no HCV
infection was confirmed in this study, suggesting that
HCV is not a major health problem in the province. This
is in line with results from Maputo and Malawi where the
prevalence of active HCV infection confirmed by molecu-
lar methods was below 1% in both sites [20,23]. Of note,
anti-HCV EIA disclosed also about 10% of false positive
results that could not be confirmed with the INNO- LIA
HCV, like observed elsewhere in Africa [20,23,25]. Since
this study, HCV screening of blood donation has been
implemented in Tete, and since 2010 in the rest of the
country as well, in accordance with the 2008 WHO
recommendation for universal HCV testing [1]. However
cost-effectiveness remains an issue for low-resource set-
tings with very low HCV prevalence [25,26]. In the blood
bank of Tete, only the cost of the rapid HCV screening
tests represents an additional amount of at least 7,000
USD annually, for a few prevented infections. Although
innovative testing strategies could be explored in Tete
[27], it is likely that HCV screening could become really
cost-effective only if the prices of available rapid tests were
drastically reduced.
The proportion of young voluntary donors was rather
high in comparison with other African countries where
it reaches only 20-30% of the blood donors [28,29]. Not
surprisingly, they were less often infected by blood-
borne pathogens [28-30]. Although already important,
t h ee f f o r t sp r o v i d e db yt h eT e t eb l o o db a n km a n a g e r s
to select low-risk groups are for sure still worth being
amplified.
In contrast, the selection power of the questionnaire
was somehow disappointing. Hepatitis B carriage was
rather well discriminated (mainly because of the ques-
tion 4), but HIV infection and syphilis were as prevalent
in the deferred as in the non-deferred group. We did
not investigate specifically this issue, but reasons contri-
buting to this low performance may include the rather
time-consuming, vague and redundant questionnaire
design, favoring a speedy and inadequate question-
answer process, the lack of privacy to answer honestly
to some delicate questions or the difficulties for both
the candidate donors and the blood bank staff in inter-
preting/translating in local language some questions not
immediately obvious or not culturally adapted to rural
Africa (questions 3, 5-8, 14). We suggest to both the
local and national health authorities to design and
implement a shorter, simpler and more contextualized
screening questionnaire, and to re-evaluate its discrimi-
native value in similar real-life settings.
This study has also highlighted that pre-donation
screening of TTI with rapid tests may be safe in settings
where there is no alternative, if all quality procedures
are respected. In transfusion medicine, false negative
screening results are of course the most harmful, and
this was fortunately not observed here with the tests
locally used. However, blood is a life-saving product
extremely difficult to obtain. The harm of deferring
unnecessarily a large number of potential donors and of
communicating to them incorrect test results should not
be underestimated. In collective donations where blood
is often tested subsequently, destroying large amounts of
blood bags is a huge waste of time, energy and money
in already overstretched settings. Erroneous laboratory
results may go undetected in the absence of quality con-
trol, and may be due to multiple causes such as intrinsic
weaknesses of a test not produced under strict quality
regulations, inadequate conservation and manipulation,
or inappropriate local validation. Quality assurance and
control are therefore critical issues; surprisingly how-
ever, it has been difficult during our research to find
independent and transparent technical information on
laboratory test performances, on appropriate conditions
for purchase, transport and conservation, or on the pro-
cesses of test validation, prequalification, approval or
recommendation. There is an urgent need to make this
information more accessible for appropriate decision
making particularly in resource-constrained blood banks.
Conclusion
This study demonstrates the substantial risk of transfu-
sion-transmissible infections in Tete Province, Mozam-
bique, except for hepatitis C. Targeting of donors with
lower risk profile, contextualization of the screening
questionnaire, constant supply of quality-assured rapid
Stokx et al. BMC Infectious Diseases 2011, 11:141
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Page 7 of 8or simple screening tests and rigorous quality control
are critical elements at reach of resource-constrained
settings to improve access to safe blood.
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